Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZTC -- Ignore unavailable to you. Want to Upgrade?

To: kinkblot who wrote (611)	9/14/1999 5:43:00 PM
From: kinkblot	Read Replies (1) \| Respond to of 752

Centocor's study of REMICADE for rheumatoid arthritis to be unblinded: prnewswire.com From Genzyme Transgenics' 1998 10-K, BUSINESS / Transgenic Products Under Development Monoclonal Antibodies. Monoclonal antibodies are immune system proteins that can find and attach to specific biological targets in the body. Recent advances in developing humanized and human antibodies, single chain antibodies and conjugated antibodies have added to the potential value of these therapeutic agents. More than 50 monoclonal antibodies are now in clinical trials sponsored by pharmaceutical and biotechnology companies with many more in development as therapeutics for cancer, cardiovascular disease, immune system disorders and for use against a wide variety of infectious agents, such as viruses and bacterial infections. Monoclonal antibodies and assembled antibodies are a major area of focus for GTC. During 1998, the Company received a US patent granting it exclusive rights to the production of monoclonal and assembled antibodies in commercial quantities in the milk of transgenic mammals. To date, the company has produced 13 antibodies, and is currently actively working with five different partners, including Centocor, Bristol-Myers Squibb, BASF/Knoll, Progenics, and an unnamed West Coast biotechnology company to develop therapeutic antibodies for diseases including rheumatoid arthritis, cancer, psoriasis and AIDS. GTC anticipates entering the clinic with the first transgenically-produced version of a therapeutic antibody during 1999. ---------------------/- Plausible explanation for today's move. First 52-week high since Oct 97.